Fonar Corporation (FONR)vsWaters Corporation (WAT)
FONR
Fonar Corporation
$18.59
+0.98%
HEALTHCARE · Cap: $92.74M
WAT
Waters Corporation
$301.92
+0.04%
HEALTHCARE · Cap: $29.33B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 2902% more annual revenue ($3.17B vs $105.43M). WAT leads profitability with a 20.3% profit margin vs 7.1%. FONR trades at a lower P/E of 13.3x. WAT earns a higher WallStSmart Score of 60/100 (C).
FONR
Hold42
out of 100
Grade: D
WAT
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-146.1%
Fair Value
$7.55
Current Price
$18.59
$11.04 premium
Margin of Safety
-349.9%
Fair Value
$73.17
Current Price
$301.92
$228.75 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Attractively priced relative to earnings
Strong operational efficiency at 33.8%
Safe zone — low bankruptcy risk
Every $100 of equity generates 29 in profit
Keeps 20 of every $100 in revenue as profit
Areas to Watch
4.3% revenue growth
Smaller company, higher risk/reward
ROE of 5.8% — below average capital efficiency
7.1% margin — thin
Moderate valuation
Earnings declined 3.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : FONR
The strongest argument for FONR centers on Price/Book, P/E Ratio.
Bull Case : WAT
The strongest argument for WAT centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 20.3% and operating margin at 33.8%. PEG of 1.25 suggests the stock is reasonably priced for its growth.
Bear Case : FONR
The primary concerns for FONR are Revenue Growth, Market Cap, Return on Equity.
Bear Case : WAT
The primary concerns for WAT are P/E Ratio, EPS Growth.
Key Dynamics to Monitor
FONR profiles as a value stock while WAT is a mature play — different risk/reward profiles.
WAT carries more volatility with a beta of 1.20 — expect wider price swings.
WAT is growing revenue faster at 6.8% — sustainability is the question.
WAT generates stronger free cash flow (126M), providing more financial flexibility.
Bottom Line
WAT scores higher overall (60/100 vs 42/100), backed by strong 20.3% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fonar Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
FONAR Corporation is engaged in the research, development, production, and marketing of Magnetic Resonance Imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company is headquartered in Melville, New York.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?